



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_185_26

You asked:

Q1. Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to?

Yes.

Q2. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

- **Myelofibrosis (ICD10 code D47.4) = 0**
- **Polycythaemia Vera (ICD10 code D45) = 0**
- **Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005) = 0**

Q3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

- **Momelotinib = 0**
- **Fedratinib = 0**

Q4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

- **Hydroxycarbamide =** We cannot provide this as we only have data for patients who attend our hydroxycarbamide clinic.
- **Interferon therapy = 7**

Q5. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy.

(First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.)

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)	**	**
Fedratinib (Inrebic)	0	0
Momelotinib (Omjjara)	0	**

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low, we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.